Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M403Revenue (TTM) $M35.9Net Margin (%)-293.0Altman Z-Score-7.6
Enterprise Value $M331EPS (TTM) $-0.4Operating Margin %-280.2Piotroski F-Score1
P/E(ttm)--Beneish M-Score-3.2Pre-tax Margin (%)-293.0Higher ROA y-yN
Price/Book10.710-y EBITDA Growth Rate %-28.3Quick Ratio3.0Cash flow > EarningsY
Price/Sales11.15-y EBITDA Growth Rate %-23.1Current Ratio3.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-35.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-128.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M243ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2016-03-31 Sold Out $1.41 - $1.97
($1.61)
$ 1.663%Sold Out0
ARNAKen Fisher 2015-12-31 Add$1.7 - $2.4
($2.04)
$ 1.66-19%Add 0.91%11,100
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 1.66-68%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 1.66-2%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 1.665%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
White Christine AnnaDirector 2016-06-13Sell18,728$1.99-16.58view
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.49-63.03view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-66.8view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-73.48view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-69.76view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-71.62view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-71.62view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-76.45view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-76.29view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-73.69view

Quarterly/Annual Reports about ARNA:

News about ARNA:

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Arena Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
Arena Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : July... Jul 21 2016
Company News for July 20, 2016 Jul 20 2016
Arena Pharmaceuticals (ARNA) Stock Gains as FDA Approves Weight-Loss Drug Jul 19 2016
Eisai And Arena Pharmaceuticals Get FDA Approval For BELVIQ XR Extended-Release Tablets Jul 19 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 19 2016
Arena Pharma stock rises 8.8% after weight-loss drug is approved Jul 19 2016
Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl)... Jul 19 2016
Eisai, Arena Pharmaceuticals Get Regulatory Approval For VENESPRI In Mexico Jul 14 2016
Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in... Jul 14 2016
Arena Pharmaceuticals stock soars after weight drug approved in Mexico Jul 14 2016
Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in... Jul 14 2016
Arena Pharmaceuticals to Slash Workforce By 73% (ARNA) Jul 05 2016
Arena (ARNA) to Cut 73% Workforce, Shifts Focus to Pipeline Jul 01 2016
Arena Pharma to lay off 73% of workforce; shares halted Jun 30 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Jun 30 2016
Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline Jun 30 2016
Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline Jun 30 2016
These Biotech Companies Are Prime For a Breakout as the Market for Smoking Cessation Products Heats... Jun 28 2016
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : June... Jun 28 2016
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 16 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)